1. Department of clinical laboratory diagnostics and genetics (St. Petersburg, Russian Federation)
2. Research laboratory of Cardiorespiratory testing (St. Petersburg, Russian Federation)
3. Research laboratory of thoracic surgery (St. Petersburg, Russian Federation)
4. Research laboratory of Figh–tech treatment (St. Petersburg, Russian Federation)

Abstract:Materials and methods of research. To study the effect of liver pathology on the pharmacokinetics of everolimus, the concentration of the drug in whole blood was determined by HPLC-MS/MS in 16 patients (men - 10, women - 6) after heart transplantation, observed in the fgbi “NMITS im. V. A. Almazova“ of the Ministry of health of the Russian Federation in the period 2016-2017, aged from 25 to 67 years (average age - 55.5 years). The average time after heart transplantation is 4.5 years. Patients received everolimus at a dose of 1.25 mg / day to 5.4 mg/day (average dose of everolimus - 2.5 mg / day).). In accordance with the distribution of nafr symptoms, the patients were divided into 2 groups (table.1): 1-4 patients with signs of nonalcoholic fatty liver disease (NAFLD), group 2 without evidence of NAFLD. The proposed method implemented using the method of high performance liquid chromatography combined with tandem mass spectrometry is straightforward, reproducible, rapid and reliable for the determination of everolimus in human whole blood with the aim of pharmacokinetic studies. Non-alcoholic fatty liver disease in patients after heart transplantation, receiving immunosuppressive therapy inhibitor mTOR everolimus, significantly affects the pharmacokinetics of the drug, achieving the target values, which can worsen the disease prognosis and quality of life.

• References total 11 ⇓ :: .
  1. Khalilulin TR, Garmash IV, Malaya IP, 2012. Clinico-pharmacological studies in patients with impaired liver function. Journal of Clinical pharmacology and therapy, 21 (2): 30–33.
  2. All-Russian public organization of transplantologists, "Russian Transplant Society", 2012. National clinical recommendations "Heart transplantation". www.transpl.ru.
  3. Lazebnik LB, Radchenko VG, Golovanova EV, Seliverstov PV and others, 2012. Non-alcoholic fatty liver disease: a clinic, diagnosis, treatment (recommendations for therapists, 2nd version). www.nogr.org.
  4. S. G. Zubova, J. V. Shitikova, Т. V. Pospelov, 2012. TOR – the centric concept of regulation of mitogenic, metabolic and energy signaling pathways in a cell. Cytology, 54 (8).
  5. M.I. Volkova, D. A. Nosov, V. A. Chernyaev et al., 2016. Efficacy and safety of everolimus in patients with advanced renal cell carcinoma (the results of a Russian multicenter observational study). Oncourology, 12: 18–27.
  6. A. N. Esaulenko, 2008. Therapeutic drug monitoring. Clinical and laboratory consultation, 3 (22): 6–10.
  7. Hallvard Holdaas, Paolo De Simone, Andreas Zuckermann, 2016. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation: 4369574, 11 pages.
  8. Jerome Dumortier, Sebastian Dharancy, Yvon Calmus, 2016. Use of everolimus in liver transplantation: The French experience. Transplantation Reviews, 30: 161–170.
  9. O.N. Reznik, A. N. Ananiev, I. V. Ulyankin, 2010. Early appointment of everolimus for kidney transplantation from donors with extended criteria. Bulletin of transplantology and artificial organs, 12: 19–26.
  10. Clinical recommendations: drug monitoring and interchangeability of original and generic immunosuppressants with a narrow therapeutic index, 2014. www.transpl.ru.
  11. N. V. Apanasenko, P. V. Kudan, F. S. Baranova, V. Yu., V. Yu. Abramov, 2013. Determination of the concentration of cyclosporin A in the blood by liquid chromatography mass spectrometry. // Clinical laboratory diagnostics, 6: 10–13.

Full text is published :
OPTIMIZATION OF THE MONITORING OF CONCENTRATIONS OF EVEROLIMUS IN PATIENTS AFTER HEART TRANSPLANTATION ON THE BACKGROUND OF LIVER PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2018;150(02):68-73
Read & Download full text